Methods.
Based on biologics and other anti-rheumatic agent prescriptions, we
divided all patients into either the biologics group or the
non-biologics group. The outcomes were the incidence rate of each
comorbidity and the hazard ratio of each comorbidity between those using
biologics and those not. We followed patients from the index date to the
date on which the database ended.